Compare Stocks: STVN, MEDP, CRL, and ICLR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRL Charles River Laboratories International	$295.23 +1.3%	$232.83	$144.26 ▼ $299.32	$14.09B	1.38	926,954 shs	887,532 shs
ICLR Icon	$172.23 -1.2%	$164.19	$66.57 ▼ $203.91	$13.19B	1.21	1.35 million shs	391,178 shs
MEDP Medpace	$620.75 +1.3%	$547.09	$373.00 ▼ $677.90	$17.33B	1.15	347,887 shs	225,439 shs
STVN Stevanato Group	€22.60 +1.1%	€19.37	€12.89 ▼ €28.00	€6.84B	0.77	537,798 shs	291,488 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRL Charles River Laboratories International	+0.97%	+3.97%	+33.63%	+82.24%	+83.99%
ICLR Icon	+1.03%	+4.05%	+4.59%	+49.22%	-3.32%
MEDP Medpace	+0.72%	+5.27%	+15.23%	+41.55%	+31.55%
STVN Stevanato Group	+2.88%	+3.65%	+17.04%	+23.39%	-1.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRL Charles River Laboratories International	$295.23 +1.3%	$232.83	$144.26 ▼ $299.32	$14.09B	1.38	926,954 shs	887,532 shs
ICLR Icon	$172.23 -1.2%	$164.19	$66.57 ▼ $203.91	$13.19B	1.21	1.35 million shs	391,178 shs
MEDP Medpace	$620.75 +1.3%	$547.09	$373.00 ▼ $677.90	$17.33B	1.15	347,887 shs	225,439 shs
STVN Stevanato Group	€22.60 +1.1%	€19.37	€12.89 ▼ €28.00	€6.84B	0.77	537,798 shs	291,488 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRL Charles River Laboratories International	+0.97%	+3.97%	+33.63%	+82.24%	+83.99%
ICLR Icon	+1.03%	+4.05%	+4.59%	+49.22%	-3.32%
MEDP Medpace	+0.72%	+5.27%	+15.23%	+41.55%	+31.55%
STVN Stevanato Group	+2.88%	+3.65%	+17.04%	+23.39%	-1.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRL Charles River Laboratories International	2.69	Moderate Buy	$255.65	-13.41% Downside
ICLR Icon	2.41	Hold	$170.40	-1.06% Downside
MEDP Medpace	2.23	Hold	$584.18	-5.89% Downside
STVN Stevanato Group	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest STVN, MEDP, CRL, and ICLR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	MEDP Medpace	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/10/2026	CRL Charles River Laboratories International	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$235.00 ➝ $300.00
8/10/2026	CRL Charles River Laboratories International	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$300.00
8/10/2026	CRL Charles River Laboratories International	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$264.00
8/7/2026	CRL Charles River Laboratories International	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$260.00 ➝ $300.00
8/6/2026	CRL Charles River Laboratories International	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$291.00
8/6/2026	CRL Charles River Laboratories International	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$215.00 ➝ $282.00
8/6/2026	CRL Charles River Laboratories International	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$180.00 ➝ $310.00
8/5/2026	CRL Charles River Laboratories International	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00
8/5/2026	CRL Charles River Laboratories International	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/31/2026	ICLR Icon	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$194.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRL Charles River Laboratories International	$4.00B	3.52	$22.35 per share	13.21	$59.62 per share	4.95
ICLR Icon	$8.29B	1.59	$16.82 per share	10.24	$122.48 per share	1.41
MEDP Medpace	$2.53B	6.85	$17.36 per share	35.75	$15.54 per share	39.95
STVN Stevanato Group	€1.34B	5.10	€0.92 per share	24.61	€5.95 per share	3.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRL Charles River Laboratories International	-$144.34M	-$4.85	N/A	23.52	3.00	-5.96%	15.75%	6.51%	11/4/2026 (Estimated)
ICLR Icon	$229.34M	$4.26	40.43	15.92	7.14	3.99%	8.02%	4.56%	10/28/2026 (Estimated)
MEDP Medpace	$451.12M	$17.06	36.39	32.38	2.71	17.67%	110.15%	24.84%	10/28/2026 (Estimated)
STVN Stevanato Group	€158.21M	€0.56	40.36	27.90	1.78	10.99%	10.43%	6.16%	N/A

Latest STVN, MEDP, CRL, and ICLR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	CRL Charles River Laboratories International	$2.77	$3.02	+$0.25	-$0.03	$980.53 million	$1.00 billion
8/5/2026	Q2 2026	STVN Stevanato Group	€0.15	€0.14	-€0.01	€0.08	N/A	€302.00 million
7/30/2026	Q1 2026	ICLR Icon	$2.55	$2.56	+$0.01	$0.94	$2.00 billion	$2.06 billion
7/22/2026	Q2 2026	MEDP Medpace	$3.98	$4.25	+$0.27	$4.25	$689.51 million	$707.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRL Charles River Laboratories International	N/A	N/A	N/A	N/A	N/A
ICLR Icon	N/A	N/A	N/A	N/A	N/A
MEDP Medpace	N/A	N/A	N/A	N/A	N/A
STVN Stevanato Group	N/A	N/A	N/A	N/A	1 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRL Charles River Laboratories International	0.92	1.35	1.04
ICLR Icon	0.23	0.95	0.95
MEDP Medpace	N/A	0.73	0.73
STVN Stevanato Group	0.21	1.61	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRL Charles River Laboratories International	98.91%
ICLR Icon	95.61%
MEDP Medpace	77.98%
STVN Stevanato Group	N/A

Insider Ownership

Company	Insider Ownership
CRL Charles River Laboratories International	1.30%
ICLR Icon	44.00%
MEDP Medpace	20.50%
STVN Stevanato Group	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRL Charles River Laboratories International	19,700	47.74 million	47.12 million	Optionable
ICLR Icon	40,100	76.57 million	42.88 million	Optionable
MEDP Medpace	6,200	27.91 million	22.19 million	Optionable
STVN Stevanato Group	6,010	302.84 million	300.72 million	Optionable

STVN, MEDP, CRL, and ICLR Headlines

Recent News About These Companies

Standard BioTools (NASDAQ:LAB) vs. Stevanato Group (NYSE:STVN) Head-To-Head Analysis

August 14, 2026 | americanbankingnews.com

Royal Bank of Canada Grows Stock Position in Stevanato Group S.p.A. $STVN

August 13, 2026 | marketbeat.com

Stevanato Group Details Mid-2026 Performance and Risk Landscape in Unaudited Interim Report

August 12, 2026 | theglobeandmail.com

Stevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Buy" from Brokerages

August 12, 2026 | americanbankingnews.com

Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Recommendation of "Buy" from Brokerages

August 12, 2026 | marketbeat.com

Insider Selling: Stevanato Group (NYSE:STVN) Director Sells €40,642.07 in Stock

August 11, 2026 | insidertrades.com

Stevanato Group (NYSE:STVN) CFO Lago Marco Dal Sells 4,209 Shares of Stock

August 11, 2026 | americanbankingnews.com

Stevanato Group (NYSE:STVN) Director Luciano Santel Sells 2,023 Shares of Stock

August 10, 2026 | marketbeat.com

Insider Selling: Stevanato Group (NYSE:STVN) Director Sells 2,045 Shares of Stock

August 10, 2026 | marketbeat.com

Insider Selling: Stevanato Group (NYSE:STVN) CFO Sells €84,558.81 in Stock

August 10, 2026 | marketbeat.com

Stevanato Group Q2 Earnings Call Highlights

August 9, 2026 | marketbeat.com

Stevanato Group Q2 2026 Results Highlight Shift to High-Value Drug Delivery Systems

August 6, 2026 | tipranks.com

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

August 6, 2026 | finance.yahoo.com

Stevanato Group S.p.A.

August 5, 2026 | fool.com

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

August 5, 2026 | zacks.com

335,493 Shares in Stevanato Group S.p.A. $STVN Purchased by Confluence Investment Management LLC

August 5, 2026 | marketbeat.com

Stevanato targets €335M-€345.2M adjusted EBITDA in 2026 following Balda C. Brewer divestiture

August 4, 2026 | seekingalpha.com

Stevanato Group Q2 2026 Earnings Call: Complete Transcript

August 4, 2026 | benzinga.com

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Stevanato Group (NYSE:STVN) Stock Price Down 5.1% - Should You Sell?

August 4, 2026 | marketbeat.com

Stevanato Group (NYSE:STVN) Releases Earnings Results, Beats Expectations By $0.01 EPS

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN, MEDP, CRL, and ICLR Company Descriptions

Charles River Laboratories International NYSE:CRL

$295.23 +3.78 (+1.30%)

As of 03:58 PM Eastern

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Icon NASDAQ:ICLR

$172.23 -2.03 (-1.16%)

As of 04:00 PM Eastern

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Medpace NASDAQ:MEDP

$620.75 +8.11 (+1.32%)

As of 04:00 PM Eastern

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Stevanato Group NYSE:STVN

€22.60 +0.25 (+1.12%)

As of 03:58 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STVN, MEDP, CRL, and ICLR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STVN, MEDP, CRL, and ICLR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STVN, MEDP, CRL, and ICLR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN, MEDP, CRL, and ICLR Company Descriptions

Charles River Laboratories International NYSE:CRL

Icon NASDAQ:ICLR

Medpace NASDAQ:MEDP

Stevanato Group NYSE:STVN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STVN, MEDP, CRL, and ICLR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STVN, MEDP, CRL, and ICLR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STVN, MEDP, CRL, and ICLR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN, MEDP, CRL, and ICLR Company Descriptions

Charles River Laboratories International NYSE:CRL

Icon NASDAQ:ICLR

Medpace NASDAQ:MEDP

Stevanato Group NYSE:STVN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools